Spark Therapeutics Inc  

(Public, NASDAQ:ONCE)   Watch this stock  
Find more results for Once
77.86
+2.32 (3.07%)
After Hours: 77.86 0.00 (0.00%)
Aug 22, 4:27PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 75.93 - 78.00
52 week 35.07 - 80.89
Open 75.98
Vol / Avg. 0.00/638,900.00
Mkt cap 2.79B
P/E     -
Div/yield     -
EPS -6.38
Shares 31.25M
Beta     -
Inst. own 96%
Aug 11, 2017
Q2 2017 Spark Therapeutics Inc Earnings Release (Estimated)
Aug 2, 2017
Q2 2017 Spark Therapeutics Inc Earnings Call - Webcast
Jun 22, 2017
Spark Therapeutics Inc at JPMorgan European Healthcare Conference
Jun 14, 2017
Spark Therapeutics Inc at Goldman Sachs Global Healthcare Conference
Jun 6, 2017
Spark Therapeutics Inc at Jefferies Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -5013.37% -612.66%
Operating margin -5191.44% -621.32%
EBITD margin - -548.15%
Return on average assets -97.52% -35.15%
Return on average equity -115.22% -39.84%
Employees 213 -
CDP Score - -

Address

3737 Market St Ste 1300
PHILADELPHIA, PA 19104-5543
United States - Map
+1-212-7906248 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Officers and directors

Steven M. Altschuler M.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Katherine A. High M.D. President, Chief Scientific Officer, Director
Age: 65
Bio & Compensation  - Reuters
Jeffrey D. Marrazzo Chief Executive Officer, Co-Founder, Director
Age: 38
Bio & Compensation  - Reuters
Stephen W. Webster Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
John Furey Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Joseph W. La Barge Esq. General Counsel
Age: 45
Bio & Compensation  - Reuters
Daniel R. Faga Chief Business Officer
Age: 37
Bio & Compensation  - Reuters
Lars G. Ekman M.D., Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Anand Mehra M.D. Independent Director
Age: 41
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 53
Bio & Compensation  - Reuters